ImmuCell Corporation (Nasdaq: ICCC) reported preliminary, unaudited total product sales of $7.2 million for the three months ended June 30, 2026, an 11.5% increase from $6.4 million in the same period of 2025, according to a company press release.

Domestic sales drove the quarterly result, rising 27.7% to $6.2 million from $4.9 million a year earlier. International sales fell 38.9% to $1.0 million from $1.6 million in the prior-year quarter.

By product, Tri-Shield First Defense sales reached $4.9 million in Q2 2026, up 8.3% from $4.5 million, while Dual-Force and other sales rose 19.1% to $2.3 million from $1.9 million.

For the six months ended June 30, 2026, total product sales were $17.5 million, a 20.9% increase from $14.5 million in the first half of 2025. Domestic sales for the half-year period grew 32.5% to $16.0 million, while international sales declined 35.7% to $1.6 million. Tri-Shield First Defense sales for the six-month period totaled $12.8 million, up 25.1%, and Dual-Force and other sales reached $4.8 million, a 10.9% gain.

CFO Timothy Fiori noted that the quarterly international sales decline of $0.6 million compared to 2025 occurred in a period when the prior year had benefited from distributors replenishing inventory following an extended backorder period. The company said it believes end-customer demand remains strong, particularly in Canada.

ImmuCell plans to host a conference call on August 14, 2026, at 9:00 AM ET to discuss complete financial results for the quarter ended June 30, 2026.